Posted by Michael Wonder on 09 Apr 2019
Mavenclad (cladribine) tablets now covered by Express Scripts
8 April 2019 - Within a week of FDA approval, Mavenclad has formulary coverage with one of the leading pharmacy benefit managers in the U.S.
EMD Serono. today announced that Express Scripts is covering on its formulary the oral multiple sclerosis (MS) therapy, Mavenclad (cladribine) tablets, which was approved by the U.S. FDA on 29 March 2019. Express Scripts has over 80 million members nationally, including thousands of people living with MS.
